Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346743 | 1.00 | BCHE (0.57) | BCHEKMT2AKDM4CMTNR1BKDM4E | |
| SCHEMBL1680336 | 1.00 | BCHE (0.57) | BCHEKMT2AKDM4CMTNR1BKDM4E | |
| Hydrochloric Acid SCHEMBL987382 | 0.99 | BCHE (0.56) | BCHEKMT2AKDM4CMTNR1BKDM4E | |
| Acetic Acid SCHEMBL990742 | 0.94 | MTNR1B (0.54) | BCHEKMT2AKDM4CMTNR1BKDM4E | |
| Acetic Acid SCHEMBL3169809 | 0.94 | MTNR1B (0.54) | BCHEKMT2AKDM4CMTNR1BKDM4E | |
| Hydrochloric Acid SCHEMBL3654652 | 0.91 | BCHE (0.47) | BCHEKMT2AKDM4CMTNR1BKDM4E | |
| SCHEMBL12200036 | 0.91 | BCHE (0.47) | BCHEKMT2AKDM4CMTNR1BKDM4E | |
| SCHEMBL6391182 | 0.90 | ADRB2 (0.53) | BCHEKMT2AKDM4C | |
| SCHEMBL4026249 | 0.90 | BCHE (0.58) | BCHEKMT2AKDM4CKDM4EMAPT | |
| SCHEMBL4027169 | 0.88 | BCHE (0.51) | BCHEKMT2AKDM4CMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010064212-A1 | METHOD FOR OBTAINING AN OPTICALLY PURE 1,2,3,4 TETRAHYDRO-ISOQUINOLINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-10 | — | — | WO | claimed |
| EP-2227454-B1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-1751111-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| EP-1751111-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8314238-B2 | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8247560-B2 | Trisubstituted 3,4-dihydro-1H-isoquinolin compound, process for its preparation, and its use | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-21 | — | — | US | disclosed |
| EP-2227455-B1 | TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-12 | — | — | EP | disclosed |
| WO-2011001373-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY PURE TRISUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | WO | disclosed |
| US-20100305325-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100256182-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | AISSAOUI HAMED | 2010-10-07 | — | — | US | disclosed |
| WO-2005118548-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118548-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-15 | — | — | WO | disclosed |
| EP-1379523-B1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-07-27 | — | — | EP | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6815451-B2 | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-11-09 | — | — | US | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-06-10 | — | — | US | disclosed |
| EP-1379523-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002076979-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | BCHE 831/4885KMT2A 2565/4885KDM4C 1980/4885 |
| US-20100256182-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | CYP4B1, RECQL, NQO1 | BCHE 1021/4885KMT2A 2266/4885KDM4C 583/4885 |
| US-20100305325-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE | DHPS, CISD1, CISD2 | BCHE 1728/4885KMT2A 1871/4885KDM4C 1477/4885 |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | UTS2R, NTSR2, NTSR1 | BCHE 1547/4885KMT2A 2540/4885KDM4C 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.